Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: Breast Cancer
Interventions: flow cytometry, immunoenzyme technique, laboratory biomarker analysis; Other
Lead sponsor: University of Arizona; Other
Eligibility: Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Breast Neoplasm
Interventions: Vinorelbine, Capecitabine; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bone Cancer, Chondrosarcoma, Ewing's Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Bone Necrosis, Bone Sarcoma, Osteomyelitis
Interventions: Feraheme, Magnetic Resonance Imaging (MRI) scan; Drug · Procedure
Lead sponsor: Heike E Daldrup-Link; Other
Eligibility: 10 Years to 21 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetic Foot Ulcers
Interventions: Santyl, Tegaderm Hydrogel; Drug
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Interventions: Oral repotrectinib (TPX-0005); Drug
Lead sponsor: Turning Point Therapeutics, Inc.; Industry
Eligibility: Up to 25 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 20
States / cities: Los Angeles, California • Aurora, Colorado • Orlando, Florida + 14 more

Conditions: Melanoma, Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
Interventions: 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Central Centrifugal Cicatricial Alopecia
Interventions: Calcipotriol, Subject's already prescribed drug; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Cytal Wound Matrix 1-Layer, Standard of Care (SOC); Device · Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland

Conditions: Systemic Lupus Erythematosus
Interventions: Ortho-Novum 777; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 15
States / cities: Los Angeles, California • Chicago, Illinois • Shreveport, Louisiana + 11 more

Conditions: Acne
Interventions: Epiduo® Forte Gel, Adapalene and Benzoyl Peroxide Gel, placebo gel; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,001 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 18
States / cities: Mesa, Arizona • Tucson, Arizona • Anaheim, California + 14 more

Conditions: Chronic Plaque Psoriasis
Interventions: alefacept, polyvalent pneumococcal vaccine; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Birmingham, Alabama • San Diego, California • New York, New York + 1 more

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer
Interventions: Amnion-Intermediate-Chorion, Amnion-Chorion-Amnion, Standard of Care; Other · Procedure
Lead sponsor: Cellution Biologics; Industry
Eligibility: 18 Years to 98 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Jacksonville, Florida • Cincinnati, Ohio • Weslaco, Texas + 1 more

Conditions: Metastatic Breast Cancer
Interventions: Erdafitinib, Palbociclib, Fulvestrant; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • New York, New York • Pittsburgh, Pennsylvania + 3 more

Conditions: Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
Interventions: [68Ga]Ga-ABY-025; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: doxorubicin hydrochloride, cyclophosphamide, filgrastim, paclitaxel albumin-stabilized nanoparticle formulation, trastuzumab, laboratory biomarker analysis, quality-of-life assessment; Drug · Biological · Other + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Melanoma
Interventions: CP 870,893, Peptides, Oncovir poly IC:LC; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Ixabepilone, Trastuzumab, Carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 12
States / cities: Fort Myers, Florida • Augusta, Georgia • Terre Haute, Indiana + 8 more

Conditions: Hyper-IgM Syndrome, Ectodermal Dysplasia
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: cisplatin, etoposide, ifosfamide, Mesna; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Breast Implant; Complications
Interventions: Insertion of Tissue Expander with Fluid Reservoir; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
Interventions: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks; Genetic
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2037
U.S. locations: 9
States / cities: Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more

Conditions: Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
Interventions: TH1902; Drug
Lead sponsor: Theratechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Detroit, Michigan • Grand Rapids, Michigan • Gettysburg, Pennsylvania + 2 more

Conditions: Breast Cancer, Colon Cancer, Lung Cancer
Interventions: survey, Audio record; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 5
States / cities: Jamaica, New York • New York, New York • Queens, New York + 1 more

Search by objective public record fields.

Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer

Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer

Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers

The Effects of Indocyanine Green Angiography (IGA) on Deep Inferior Epigastric Artery Perforator (DIEP) Flap Design and Post-Operative Fat Necrosis

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

Safety of Estrogens in Lupus: Birth Control Pills

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States

Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer

Tissue Expansion in Breast Reconstruction Without Drains

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

TH1902 in Patients With Advanced Solid Tumors

Physician Use of Non-English Language Skills in Cancer Care